Androgel

Usually, a case has a winner and a loser—or at least somebody wins enough to be happy and the other loses enough to be upset. In this case, the winner was the U.S. government, but it didn’t win by much. The loser is Actavis (NYSE: ACT) and the rest of the pharma industry but it didn’t lose by...